Literature DB >> 32577762

Men more vulnerable to COVID-19: explained by ACE2 on the X chromosome?

Iziah E Sama1, Adriaan A Voors1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32577762      PMCID: PMC7337767          DOI: 10.1093/eurheartj/ehaa526

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


× No keyword cloud information.
This commentary refers to ‘ The apparent superiority of women over men in not succumbing to COVID-19 is not completely understood. Therefore, examination of the sex-distinguishing genetics of angiotensin-converting enzyme 2 (ACE2), the host receptor that binds SARS coronaviruses, might help explain this sex disparity. The ACE2 gene is located on the X chromosome and is expressed in various tissues, including the heart, kidneys, and testes. Endogenous soluble ACE2 (found in the circulation) is shed from the cell membrane-bound form and the enzyme responsible for this shedding is ADAM17,, which is also membrane anchored. We recently postulated that the co-expression of ACE2 and ADAM17 in the testes (Supplementary figures 5 and 6 in Sama et al.) might partially explain why plasma ACE2 concentrations are higher in men than in women. We agree with the commentary by Culebras and Hernández that the mere occurrence of ACE2 on the X chromosome could also be important in explaining why men would suffer more from ACE2-related diseases than women. In general, based on gene dosage, men suffer more often from X-linked disease traits than do women. Future studies relating ACE2 levels to its genomic context, copy number variations, X-inactivation, and various co-morbidities and other (epi)genetic factors are required to improve our understanding of the gender-based disparities in ACE2-related pathophysiology and its relationship to the COVID-19 pandemic.
  5 in total

Review 1.  COVID-19: Why does disease severity vary among individuals?

Authors:  Saeed Samadizadeh; Maha Masoudi; Mostafa Rastegar; Vahid Salimi; Mahsa Bataghva Shahbaz; Alireza Tahamtan
Journal:  Respir Med       Date:  2021-03-05       Impact factor: 4.582

2.  Risk factors for mortality in COVID-19 patients in sub-Saharan Africa: A systematic review and meta-analysis.

Authors:  Ben Bepouka; Nadine Mayasi; Madone Mandina; Murielle Longokolo; Ossam Odio; Donat Mangala; Marcel Mbula; Jean Marie Kayembe; Hippolyte Situakibanza
Journal:  PLoS One       Date:  2022-10-17       Impact factor: 3.752

3.  TNF-α Blockers Showed Prophylactic Effects in Preventing COVID-19 in Patients with Rheumatoid Arthritis and Seronegative Spondyloarthropathies: A Case-Control Study.

Authors:  Mansour Salesi; Behrokh Shojaie; Ziba Farajzadegan; Naghmeh Salesi; Erfan Mohammadi
Journal:  Rheumatol Ther       Date:  2021-07-23

4.  Predictors of mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis.

Authors:  Changcheng Shi; Limin Wang; Jian Ye; Zhichun Gu; Shuying Wang; Junbo Xia; Yaping Xie; Qingyu Li; Renjie Xu; Nengming Lin
Journal:  BMC Infect Dis       Date:  2021-07-08       Impact factor: 3.090

5.  Understanding COVID-19: in the end it is the endothelium-what else?

Authors:  Thomas F Lüscher
Journal:  Eur Heart J       Date:  2020-08-21       Impact factor: 29.983

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.